Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Account Payables (2016 - 2025)

Coherus Oncology's Change in Account Payables history spans 13 years, with the latest figure at -$5.1 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 180.23% year-over-year to -$5.1 million; the TTM value through Dec 2025 reached -$19.6 million, down 396.6%, while the annual FY2025 figure was -$19.6 million, 396.6% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$5.1 million at Coherus Oncology, up from -$15.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $39.5 million in Q2 2024 and bottomed at -$50.4 million in Q3 2024.
  • The 5-year median for Change in Account Payables is $409500.0 (2021), against an average of -$170400.0.
  • The largest annual shift saw Change in Account Payables crashed 1000.88% in 2021 before it soared 2243.35% in 2022.
  • A 5-year view of Change in Account Payables shows it stood at -$29.6 million in 2021, then skyrocketed by 105.4% to $1.6 million in 2022, then plummeted by 149.03% to -$785000.0 in 2023, then surged by 907.9% to $6.3 million in 2024, then tumbled by 180.23% to -$5.1 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Change in Account Payables are -$5.1 million (Q4 2025), -$15.3 million (Q3 2025), and -$12.2 million (Q2 2025).